지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학위논문
- 저자정보
- 발행연도
- 2018
- 저작권
- 서울대학교 논문은 저작권에 의해 보호받습니다.
이용수0
이 논문의 연구 히스토리 (2)
- 이 논문의 후속연구가 궁금하신가요?
- 연관 학술논문 또는 학술발표를 통해 보다 발전된 연구결과를 확인하실 수 있습니다.
- 이 논문의 연구 히스토리 확인하기
초록· 키워드
오류제보하기
Background: Previously, a linked pharmacokinetic-pharmacodynamic model (Kim model) of propofol was developed for children aged 2 to 12 years, allowing target-controlled infusion. Despite an increasing need for intravenous anesthesia using propofol during surgery in children younger than two years of age, no pharmacokinetic-pharmacodynamic model of propofol has been developed for this population. Therefore, in this study, we performed an external validation of Kim’s propofol model for children aged less than two years.
Methods: Twenty-four children below the age of two years undergoing neurosurgery were enrolled. Anesthetic induction was commenced using a target-controlled infusion of 2% propofol based on Kim model and continuous infusion of remifentanil under bispectral index (BIS) monitoring. The target effect-site concentration of propofol was set to 2, 3, 4, and 5 ?g/ml, each followed by arterial blood sampling after 10 min of equilibrium. Population estimates of pooled bias, inaccuracy, divergence, and wobble were calculated to evaluate the performance of the Kim model.
Results: A total of 95 plasma concentrations and 91 BIS values were used for evaluation of the Kim model. For plasma concentration of propofol, the bias was -0.96% and inaccuracy was 21.0%. For BIS, the bias was -7.7% and inaccuracy was 20.6%.
Conclusions: The pooled bias and inaccuracies from the pharmacokinetic-pharmacodynamic predictions were within clinically acceptable range. Therefore, the Kim model may be applicable for propofol target-controlled infusion in children under two years of age.
Methods: Twenty-four children below the age of two years undergoing neurosurgery were enrolled. Anesthetic induction was commenced using a target-controlled infusion of 2% propofol based on Kim model and continuous infusion of remifentanil under bispectral index (BIS) monitoring. The target effect-site concentration of propofol was set to 2, 3, 4, and 5 ?g/ml, each followed by arterial blood sampling after 10 min of equilibrium. Population estimates of pooled bias, inaccuracy, divergence, and wobble were calculated to evaluate the performance of the Kim model.
Results: A total of 95 plasma concentrations and 91 BIS values were used for evaluation of the Kim model. For plasma concentration of propofol, the bias was -0.96% and inaccuracy was 21.0%. For BIS, the bias was -7.7% and inaccuracy was 20.6%.
Conclusions: The pooled bias and inaccuracies from the pharmacokinetic-pharmacodynamic predictions were within clinically acceptable range. Therefore, the Kim model may be applicable for propofol target-controlled infusion in children under two years of age.
목차
1. Introduction 12. Methods 22.1 Ethics approval 22.2 Study population 22.3 Study protocol 22.4 Measurement of plasma concentration of propofol 42.5 Calculation of predicted BIS 52.6 External validation 53. Results 84. Discussions 105. References 13
최근 본 자료
댓글(0)
0